QUTX 8-K/A
Quantum X Inc. (QUTX)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Act of 1934
Date of
Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant's
telephone number, including area code:
|
N/A |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| 1 |
Explanatory Note
This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K filed on January 10, 2025 (the “Original Filing”) by Two Hands Corporation (the “Company”). The Original Filing reported, the appointments of Andrew Kucharchuk and Craig Marshak as members of the Board of Directors. Due to a clerical error, the appointment of the new Chief Financial Officer was inadvertently omitted. The Company hereby amends the Original Filing to include information on the appointment in Item 5.02 below. Other than the additional information provided in Item 5.02 below, no other disclosure in the Original Filing is amended by this Form 8-K/A.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain officers; Compensatory Arrangements of Certain Officers.
On January 3, 2025, the Company accepted the resignation from Emil Assentato as the Company’s Chief Financial Officer. Effective on the same date to fill the vacancy created by Mr. Assentato’ resignation, the Board of Directors appointed Andrew Kucharchuk as the Company’s Chief Financial Officer. This resignation was not the result of any disagreement with Company on any matter relating to Company’s operations, policies or practices. Emil Assentato will continue to serve as Chief Executive Officer, President, Treasurer, Secretary and a member of the Board of Directors of the Company.
In addition, effective January 3, 2025, the Board of Directors appointed Andrew Kucharchuk and Craig Marshak as members of the
Board of Directors. The Board now consists of Emil Assentato, Andrew Kucharchuk and Craig Marshak.
The following biographical information is provided:
Andrew Kucharchuk, Chief Financial Officer and Member of the Board of Directors
Mr. Kucharchuk has been a director of Adhera Therapeutics Inc. since July 7, 2022, and currently serves as its Chief Operating Officer, a position he has held since September 30, 2022. Previously, he was Chief Executive Officer of Adhera Therapeutics from July 7, 2020, to September 30, 2022.
Mr. Kucharchuk has been a member of the Board of Directors of Theralink Technologies, Inc. (“Theralink”) since 2020, having previously served in this role from September 2015 to March 2017. His executive experience at Theralink includes roles as President and Chief Financial Officer from February 2016 to June 2020, Chief Executive Officer from November 2019 to June 2020, and Acting Chief Financial Officer from June 2020 to September 2020.
Craig Marshak, Member of the Board of Directors
Mr. Marshak has been a Managing Director at Clear Think Capital since joining the firm in March 2021. From 2018 to 2021, he served as Senior Advisor to SHR Ventures LLC, the family office of Stanley Hutton Rumbough, whose grandfather founded E.F. Hutton. During this time, he co-founded Moringa Acquisition, a NASDAQ-listed SPAC, where he serves as Vice Chairman and Co-Founder.
Since 2002, Mr. Marshak has been a Principal at Israel Venture Partners (israelventurepartners.com), a platform focused on identifying and investing in Israeli technology and healthcare companies.
Mr. Marshak began his investment banking career at Morgan Stanley in the Merchant Banking department before moving to Corporate Finance and Mergers & Acquisitions at Wertheim Schroder and later Schroders in London, England. He went on to establish the London office of Robertson Stephens and, from 1998 to 2001, was Co-Head of the Nomura Technology Merchant Banking Group in London, specializing in high-growth companies in the Israeli and Silicon Valley sectors.
| 2 |
His expertise includes advising on multi-billion-dollar restructuring assignments, such as the privatization of Israel Chemicals from Israeli government ownership, the restructuring of Koor Industries (formerly one of Israel’s largest conglomerates), and the landmark restructuring of Manville Corporation. Mr. Marshak and his team at Schroders led the entirety of the Manville engagement, which was one of the most complex restructurings of its era.
Mr. Marshak graduated summa cum laude and Phi Beta Kappa with an A.B. degree from Duke University. He was awarded the Roger Alan Opel Scholarship to the London School of Economics and later earned a J.D. from Harvard Law School.
Item 9.01 Financial Statements and Exhibits
| Exhibit No. | Document | ||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 24, 2025
TWO HANDS CORPORATION
By: /s/ Emil Assentato Emil Assentato Chief Executive Officer
|
| 3 |